The Weekly Roundup: May 5-9

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

How OX40-Targeted Therapies Might Reshape Biologic Strategy in AD

Christopher Bunick, MD, PhD, discusses the evolving role of OX40-targeted biologics in atopic dermatitis treatment ahead of the upcoming RAD conference.

Peter Lio, MD, Advocates for Personalized Pediatric Dermatology

Peter Lio, MD, discusses innovative treatments for pediatric atopic dermatitis, including microbiome therapies and botanical options.

Off-Label Ixekizumab is Effective for HS After Treatment Failure with Adalimumab

Ixekizumab shows promise in restoring clinical response for hidradenitis suppurativa patients previously unresponsive to adalimumab, highlighting new treatment options.

Gearing Up for RAD Insights From Summer Conferences

Explore vital insights on melanoma awareness, skin cancer disparities, and atopic dermatitis management in the latest issue of Dermatology Times.

Nonadherence Remains Common Concern in Dermatology

Researchers conducted a review of adherence behaviors for patients with dermatological diseases and provided an update on management strategies.

The State of Melanoma Care: Advances, Access, and the Road Ahead

This Melanoma Monday, we take a look at melanoma care in the US, from treatments to persistent gaps in access, early detection, and long-term outcomes.

Supporting Patients With Rare Genetic Skin Diseases and the Foundations Dedicated to Them

In his May letter, Christopher Bunick, MD, PhD, reflects on his journey as a physician-scientist and advocates for supporting foundations dedicated to rare skin diseases.

MJH Life Sciences Expands Beauty and Aesthetics Scope With NewBeauty

MJH Life Sciences acquires NewBeauty, merging clinical expertise with consumer-driven wellness to redefine beauty and aesthetics media.

Clinical Trial Validates Delgocitinib’s HRQoL Benefits

Delgocitinib cream significantly enhances health-related quality of life for patients with chronic hand eczema, addressing both symptoms and psychosocial impacts.

Upadacitinib Shows Promise in Reducing Cardiovascular and Thrombotic Risks in Atopic Dermatitis Patients

Researchers reported that upadacitinib may lower the incidence of major cardiovascular events and venous thromboembolism in AD.

Topical Steroid Withdrawal: Uncovering Neuroinflammatory Mechanisms

Our May cover story explores NIH’s new findings on topical steroid withdrawal, a condition now under scientific scrutiny as a distinct entity.

Nail Care’s Hidden Health Costs

Explore the hidden health risks of nail products and the urgent need for safety reforms in the nail salon industry for workers and customers alike.

Real-World Management Strategies for Alopecia Areata

Explore innovative strategies for managing alopecia areata with insights from expert Susan Taylor, MD, FAAD, highlighting breakthrough JAK inhibitors and real-world case studies.

Journal Digest: May 7

This review of the latest dermatologic studies includes insights into short- and long-term effects of topical cosmetics to dermatological procedures, adverse effects of omalizumab in urticaria, and more.

Phase 3 Trial Confirms Roflumilast’s Dual-Site Efficacy

Roflumilast foam shows significant efficacy in treating scalp and body psoriasis, enhancing patient adherence and quality of life in a recent clinical trial.

Exploring the Role of GLP-1 Receptor Agonists in Psoriasis

Explore the potential of GLP-1 receptor agonists in psoriasis management, highlighting their immunomodulatory effects and metabolic benefits for patients.

Building Trust Through Cultural Competency in Aesthetic Dermatology

Explore how cultural competency in aesthetic dermatology bridges trust gaps, ensuring inclusive care for patients of color and enhancing treatment outcomes.

AAD Partners With SOCS to Launch Inclusive Image Library

The Clinical Image Collection enhances dermatologic education by providing diverse images of skin conditions, promoting inclusivity and accurate diagnoses across all skin tones.

Evaluating Dupilumab and Upadacitinib for Head and Neck AD

New research from AAD 2025 highlights upadacitinib's effectiveness over dupilumab for treating atopic dermatitis, especially in challenging facial and neck areas.

Survey Snapshot: Chronic Hand Eczema's Clinical Burden, Treatment Gaps, and Patient Impact Revealed

We review survey data revealing diagnostic confusion, treatment gaps, and the emotional, social, and occupational toll of moderate to severe chronic hand eczema.

FDA Launches Agency-Wide AI Rollout by 2025

FDA accelerates AI integration by 2025, enhancing scientific reviews and modernizing regulatory processes for improved public health outcomes.

#DermTok: Navigating TikTok’s Acne Advice Misinformation

Social media reshapes dermatology, but misinformation about acne treatments on platforms like TikTok raises concerns among clinicians and patients alike.

Abrocitinib Shows Age-Linked Safety Differences

Recent analysis reveals abrocitinib's long-term safety in atopic dermatitis, highlighting age-related risks and the importance of tailored dosing for older patients.

Corvus Pharmaceuticals’ Soquelitinib Shows Rapid, Dose-Dependent Efficacy in Phase 1 AD Trial

Selective ITK inhibition with oral soquelitinib led to early and durable clinical responses, cytokine reduction, and increased T regulatory cells.

Switching Gears in Atopic Dermatitis: How Upadacitinib Helps Patients Reach Optimal Targets After Dupilumab Inadequacy

Data from the Level Up study shows that switching from dupilumab to upadacitinib enables more patients to achieve optimal targets of skin clearance and itch relief.

Missed Diagnoses, Missed Opportunities: Closing the Gap in Skin Cancer for Patients of Color

Explore the urgent need for improved skin cancer awareness and care for minority populations, addressing disparities in diagnosis and treatment.

Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata

Significant unmet needs were found among high-quality validation studies on the internal structure of PROMs specific to alopecia areata.

Outgoing AAD President Seemal Desai, MD, FAAD, Reflects on Challenges, Advocacy, and the Future of Dermatology

Desai reflects on his AAD presidency, addressing Medicare challenges, technological advancements, and the future of dermatology leadership.

Artax Presents Phase 2a Results of AX-158 for Plaque Psoriasis

The promising safety and efficacy results were presented at the Society for Investigative Dermatology 2025 Annual Meeting.

Collaborating for Better Aesthetics: Why Dermatology Matters in Multispecialty Medicine

Explore the evolving landscape of dermatology as experts emphasize the importance of cross-specialty collaboration and patient-centered care in aesthetic medicine.

Icotrokinra Effective in High-Impact Psoriasis Areas

Johnson & Johnson's icotrokinra shows promising results in treating moderate plaque psoriasis, especially in challenging areas like the scalp and genitals.

New-Onset Psoriasis After Abrocitinib Treatment for Atopic Dermatitis

Abrocitinib’s targeted inhibition of JAK1 offers effective control of AD, but may, in rare instances, lead to a shift in immune expression resulting in paradoxical psoriasis.